• Glaucoma

Simbrinza Generic Name & Formulations

General Description

Brinzolamide 1%, brimonidine tartrate 0.2%; oph susp; contains benzalkonium chloride.

Pharmacological Class

Carbonic anhydrase inhibitor + alpha-2 agonist.

How Supplied


Simbrinza Indications


Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.

Simbrinza Dosage and Administration

Adults and Children

<2yrs: contraindicated. ≥2yrs: 1 drop three times daily.

Simbrinza Contraindications


Neonates and infants <2yrs.

Simbrinza Boxed Warnings

Not Applicable

Simbrinza Warnings/Precautions


Sulfonamide allergy. Discontinue if serious systemic or hypersensitivity reactions occur. Increased risk of corneal edema in patients with low endothelium cell counts. Severe renal impairment (CrCl <30mL/min): not recommended. Hepatic impairment. Severe cardiovascular disease. Depression. Cerebral or coronary insufficiency. Raynaud’s phenomenon. Orthostatic hypotension. Thromboangitis obliterans. Acute angle-closure glaucoma. Remove soft contact lenses before use; may reinsert 15mins later. Pregnancy (Cat.C). Nursing mothers: not recommended.

Simbrinza Pharmacokinetics

See Literature

Simbrinza Interactions


Concomitant oral carbonic anhydrase inhibitors: not recommended. Caution with antihypertensives, cardiac glycosides, tricyclic antidepressants, MAOIs. Concomitant high-dose salicylate may produce acid-base and electrolyte alterations. May be potentiated by CNS depressants (eg, alcohol, opiates, barbiturates, sedatives, anesthetics). Separate administration of other oph drugs by ≥5 minutes.

Simbrinza Adverse Reactions

Adverse Reactions

Blurred vision, eye irritation, dysgeusia, dry mouth, eye allergy.

Simbrinza Clinical Trials

See Literature

Simbrinza Note

Not Applicable

Simbrinza Patient Counseling

See Literature